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CXCR4 coreceptor usage appears to occur less frequently among HIV-1 subtype C viruses. The aim of this study was to investigate the genetic
determinants within the V3 region of subtype C isolates able to use CXCR4. Thirty-two subtype C isolates with known phenotypes (16 R5, 8
R5X4 and 8 X4 isolates) were assessed. A subtype C-specific V3 heteroduplex tracking assay (HTA) was used to determine sample complexity,
and nucleotide sequencing analysis was used to compare characteristics associated with CCR5 and CXCR4-using isolates. There were sufficient
genetic differences to discriminate between R5 viruses and those able to use CXCR4. In general, R5 isolates had an HTA mobility ratio >0.9
whereas CXCR4-using isolates were usually <0.9. Multiple bands were more frequently seen among the dualtropic isolates. Sequence analysis of
the V3 region showed that CXCR4-using viruses were often associated with an increased positive amino acid charge, insertions and loss of a
glycosylation site, similar to HIV-1 subtype B. In contrast, where subtype B consensus V3 has a GPGR crown motif irrespective of coreceptor
usage, all 16 subtype C R5 viruses had a conserved GPGQ sequence at the tip of the loop, while 12 of the 16 (75%) CXCR4-using viruses had
substitutions in this motif, most commonly arginine (R). These findings were confirmed using a larger published data set. We therefore suggest
that changes within the crown motif of subtype C viruses might be an additional pathway to utilise CXCR4 and thus GPGQ may limit the potential
for the development of X4 viruses.
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The binding of HIV-1 to CD4 and a coreceptor facilitates the
entry of the virus into host target cells. The two major
coreceptors involved are CCR5 and CXCR4 (Deng et al.,
1996; Dragic et al., 1996; Feng et al., 1996), with CCR5 being
the most commonly used during transmission and early infection
(Michael et al., 1997). HIV-1 isolates can be differentiated based
on their ability to use these coreceptors with R5 viruses
(formerly known as non-syncytium-inducing or NSI viruses)
utilising CCR5, X4 viruses using CXCR4 and R5X4 viruses
able to use both receptors (collectively known as syncytium-
inducing or SI isolates) (Berger et al., 1998). Viruses able to use
CXCR4 emerge later in the course of infection in over 50% of
individuals infected with subtype B (Connor et al., 1997;⁎ Corresponding author. Fax: +2711 386 6453.
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the most prevalent subtype, but to date only limited numbers of
CXCR4-using viruses have been described and characterised,
with R5 viruses dominating at all stages of disease, including late
stage AIDS (Abebe et al., 1999; Batra et al., 2000; Bjorndal et
al., 1999; Cilliers et al., 2003; Johnston et al., 2003; Ping et al.,
1999). This suggests that there may be factors limiting the
development of X4 viruses in subtype C, but it is not clear
whether this is due to host immune or virological constraints.
Determining what defines a subtype C X4 virus might increase
the likelihood of identifying these viruses, improve under-
standing of the factors involved in their development, as well as
the role CXCR4 usage plays in disease progression of subtype C
HIV-1.
The third variable loop (V3) of gp120 is generally 35 amino
acids long, highly variable and a critical determinant of
coreceptor usage, although other regions such as the V1/V2
and the conserved region 4 (C4) have also been implicated
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variation of specific amino acids, increased positive amino acid
charge and glycosylation are some of the characteristics that
have been identified as influencing coreceptor usage in subtype
B. In particular, the amino acids at positions 11 and 25 are used to
distinguish between NSI (R5) and SI (R5X4 and X4) viruses,
with the latter often having a positive amino acid at these
positions (De Jong et al., 1992; Fouchier et al., 1995; Hoffman et
al., 2002). As a result, the net V3 charge is often a good indicator
and determinant of viral tropism, with a high positive charge
correlating with CXCR4 usage. An important determinant of
CCR5 usage appears to be the predicted N-linked glycosylation
site at position 6–8 within the V3 region as loss of this glycan is
associated with less efficient usage of CCR5 and in some cases
enhanced ability to use CXCR4 for entry (Ogert et al., 2001;
Polzer et al., 2002). The role of these V3 genetic characteristics
and the influence they may have on subtype C coreceptor usage
remain to be evaluated as to date only a few isolates able to use
CXCR4 have been identified in this subtype.
The V3-specific heteroduplex tracking assay (V3-HTA) has
been used to investigate the presence of multiple variants
within the V3 region in subtype B (Nelson et al., 1997). This
assay is based on the formation of heteroduplexes between the
isolate V3 sequence and a consensus V3 sequence (probe).
Divergence from the consensus sequence is then measured by
the mobility ratio of the heteroduplexes formed and represents
the variation within the V3 region, with CXCR4-using viruses
usually the most divergent (Nelson et al., 1997, 2000). A
subtype C-specific V3-HTA has previously been applied to
subtype C samples, but no CXCR4-using viruses were
identified due to the low frequency of X4 viruses in this
subtype (Ping et al., 1999). In this study, we selected 32
subtype C isolates from different patients with experimentally
determined coreceptor usage profiles (16 R5 and 16 R5X4 or
X4) and used the V3-HTA to screen for population complexityTable 1
Clinical information of the 16 R5, 8 R5X4 and 8 X4 HIV-1 subtype C isolates used
R5 isolates R





Du151(11-98) Acute 367 >500,000 R5 C
PCP1 AIDS 2 NA R5 D
CM1 AIDS 43 146,514 R5 D
CM4 AIDS 47 163,755 R5 R
SW2 AIDS 84 157,150 R5 SW
SW3 AIDS 53 261,880 R5 SW
SW4 AIDS 76 1,496,620 R5 TM
SW5 AIDS 40 1,374,235 R5 TM
SW8 AIDS 67 1,198,880 R5 D
SW9 AIDS 65 301,605 R5 D
TM3 Slow progressor 329 11,178 R5 D
TM4 Slow progressor 692 25,815 R5 SW
TM5 Slow progressor 1378 22,488 R5 SW
TM6 Slow progressor 846 108,716 R5 TM
TM10 Slow progressor 1158 685 R5 TM
TM12 Slow progressor 976 21,976 R5 TM
NA: not available.of these biological variants. Furthermore, the sequences of
these isolates were studied to determine if there were any
distinct changes in the V3 region that might be used to
differentiate CCR5 and CXCR4 usage in subtype C.
Results
V3-HTA can distinguish sample complexity within subtype
C isolates with different biological phenotypes
To investigate the complexity within the V3 region of HIV-1
subtype C samples with different phenotypes, a V3-HTA was
used to screen 16 R5 isolates, 8 R5X4 and 8 X4 isolates from
different patients at various stages of disease, including late
stage AIDS (Table 1). Two isolates from a single patient
(Du179) that were 1 year apart were both included as they
showed different coreceptor profiles. The V3 region from all
isolates was amplified and hybridised to a subtype C R5
radiolabelled probe and resolved on a polyacrylamide gel. In
general, the heteroduplexes that formed between the probe and
the R5 viruses migrated faster through the gel, close to the probe
homoduplex, while the R5X4 and X4 viruses migrated more
slowly through the gel at variable distances and often closer to
the single-stranded probe (Fig. 1). At the extreme, one R5X4
(SW30) and one X4 (TM2) had heteroduplexes that migrated
above the single-stranded probe, suggesting a high degree of
genetic difference and/or an insertion or deletion relative to the
probe. Apart from one R5 isolate (SW4) and one X4 isolate
(SW7), all the R5 and X4 isolates had single bands indicative of
homogeneous populations within the V3 region. In contrast, 5
of the 8 R5X4 isolates had multiple variants often migrating at
different distances between the single strand and homoduplex
probe. These multiple variants suggest heterogeneous mixtures
of viruses with different phenotypes and were therefore further
referred to as dual/mixed tropic (DM) viruses.in this study
5X4/X4 isolates





M9 AIDS 24 NA R5X4
u179(05-99) Chronic 279 2640 R5X4
u36 Acute 25 54,944 R5X4
P1 Rapid progressor 7 178,830 R5X4
20 AIDS 2 43,595 R5X4
30 AIDS 2 73,860 R5X4
1 Slow progressor NA 190,000 R5X4
18b Slow progressor 202 500,000 R5X4
R28 AIDS, on treatment 173 269,000 X4
u179(05-00) Chronic 231 2228 X4
u55 Acute 13 6589 X4
12 AIDS 27 68,410 X4
7 AIDS 10 NA X4
2 Slow progressor NA 25,156 X4
46b Slow progressor 4 28,613 X4
9 Slow progressor 11 296,865 X4
Fig. 1. V3-HTA of HIV-1 subtype C isolates with different biological phenotypes. PCR products from viral isolates were hybridised to a radiolabelled subtype C R5
probe and separated on a polyacrylamide gel. Heteroduplexes between the isolate and probe usually migrated between the single-stranded probe and the probe
homoduplex as shown in five separate gels.
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on the migration rate of the heteroduplex bands divided by the
migration distance of the homoduplex band from the probe. In
isolates with multiple bands, the mobility ratio for each variant
was calculated. The majority of R5 isolates clustered closer
together with a median mobility ratio of 0.94 (range 0.76–0.96)
(Fig. 2A). The three R5 isolates (TM3, CM4 and TM10) with
low mobility ratios (k<0.90) had a single deletion within the V3
region at amino acid positions 23, 24 and 25 respectively
compared to the probe sequence, which resulted in slower
migration through the gel. The mobility ratios of R5X4 and X4
isolates showed a broader range (0.52–0.93) with a median of
0.64. There was no significant difference in median k values
between R5X4 and X4 isolates, although almost all fell below
0.90. The one isolate with a mobility ratio above 0.90 (DR28)
was from a drug treated patient and had 35 amino acids similar
to the probe. A graphical display of these data relative to
coreceptor usage is shown in Fig. 2B. A mobilty ratio of 0.90
separated most R5 isolates from the CXCR4-using viruses
(p<0.001, Fisher's Exact Test).
Analysis of isolates with multiple variants
Seven isolates in this study had multiple variants in the V3
region that were clearly distinguishable on a V3-HTA. This
included one R5 isolate (SW4), five DM tropic isolates (CM9,
Du36, RP1, SW30, TM1) and one X4 isolate (SW7). In order to
analyse the different variants, molecular clones were made from
five of these isolates (TM1 and SW7 were not cloned). The V3
amino acid alignments for each of the variants were compared,
and the phenotypes of individual molecular clones were
predicted. Phenotypes were predicted based on the V3 amino
acid charge, sequence analysis and C-PSSM algorithm (Jensen
et al., 2006).
A total of five variants were cloned from the DM tropic
isolate Du36 (Fig. 3A). These variants were present in different
proportions, with variants 3 and 5 being the most common. The
V3 amino acid charge for all 5 variants was between 6.5 and 7.5,and 3 of the variants (clone numbers 2, 3 and 5) lacked the
predicted N-glycosylation site indicative of CXCR4 usage. The
mobility ratios of 4 variants were consistent with CXCR4 usage,
however, variant 1 had a higher sequence similarity to the R5
probe which may account for the dual tropism in this isolate.
Nonetheless, the C-PSSM predicted that all clones would use
CXCR4.
Sequence analysis of clones from 1 R5 and 3 additional DM
isolates with multiple bands were also investigated (Fig. 3B).
The amino acid sequences from both clones of SW4 were
identical, and this was supported by the charge and length, which
were typical of R5 viruses. The mobility differences between the
2 variants of SW4 visible on the V3-HTA were thus due to
synonymous nucleotide changes. Among the 3 DM isolates,
amino acid differences were seen between the 2 clones of each
isolate, confirming a mixture of variants. However, the C-PSSM
predicted that for CM9 and SW30 both variants used CXCR4,
while for RP1 one clone was predicted to use CCR5. The genetic
characterisations of the CXCR4 variants differed between
patients, although some commonalities in the positions were
noted. These characteristics included positively charged amino
acids at positions 11 and 25, changes in the crown motif and
insertions. Unfortunately, biological clones from these DM
isolates were not available to confirm predicted phenotypes.
V3 sequence variability of CCR5- and CXCR4-using variants
Two data sets were compiled representing CCR5- and
CXCR4-using amino acid sequences. The CCR5-using data
set was obtained from the 16 patients with R5 viruses. Single
sequences were obtained from 10 of the 16 patients with
homogenous R5X4 or X4 viruses. For two patients (SW7 and
TM1), population-based sequences were used as clones were not
available. In the remaining 4 patients with DM tropic viruses
where more than one clonal sequence was available, we selected
the sequence with the least similarity to the probe in order to
increase the sensitivity of identifying genetic characteristics
associated with CXCR4 usage. These V3 sequences from the 16
Fig. 2. Comparison of mobility ratio's (k) and coreceptor usage of subtype C isolates. (A) V3-HTA mobility ratio, number of amino acids and charge in V3 of the
variants present within the R5, R5X4 and X4 isolates. In isolates with multiple bands, all the mobility ratios are listed. (B) Association between mobility ratio (k) and
biotype. A mobility ratio of 0.90 separated most R5 from R5X4 and X4 viruses.
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and charge. The majority of CCR5-using sequences had 34–35
amino acids with no insertions, whereas CXCR4-using
sequences consisted of 32–37 amino acids due to insertions
and deletions (Fig. 4A). The V3 net amino acid charge between
CCR5 and CXCR4 usage was distinct with little overlap (Fig.
4B). The CCR5-using viruses had an amino acid charge between
+2 and +4.5, with the majority of samples having +3.5.
CXCR4-using variants ranged between +4.5 and +8 with the
highest frequency of variants having a charge of +7.5. Thus, the
CXCR4-using sequences had variable V3 length and increased
number of positively charged amino acids.
Entropy plots were performed to compare the amount of
sequence variability between the CCR5- and CXCR4-using
variants (Fig. 5A). Entropy plots graphically measure the
amount of variability at a specific site of an alignment, withhigher entropy indicative of more variation at a specific site. In
general, the CXCR4 variants were more variable across the V3
region at each specific site, with high variation at positions 11,
12, 24 and 25. The predicted N-glycosylation site (at positions
6–8) within CCR5 using viruses was conserved in all 16 R5
isolates but highly variable in the CXCR4-using samples.
Similarly, the crown motif within the V3 for all R5 isolates was
GPGQ, compared to CXCR4-using variants that showed
variation in this motif (Fisher's Exact Test, p<0.0001).
The frequency and type of amino acid substitutions at each
site were determined for the CCR5- and CXCR4-using isolates
(Fig. 5B). Although these results represent small numbers (16
CCR5- and 16 CXCR4-using isolates), CCR5 usage was
associated with less amino acid substitutions compared to
CXCR4 usage. In particular, a variety of amino acids were seen
at positions 11 and 25 within CXCR4-using viruses, but these
Fig. 3. Analysis of molecular clones from HIV-1 subtype C isolates with multiple variants. The variants were labelled from the bottom (highest mobility ratio) to the top
of the gel. Amino acid alignments indicating only the differences within these populations, number of amino acids and charge of the V3 region are shown. Predicted
phenotype based on charge, sequence analysis and C-PSSM score. (−) indicates amino acids not present, (aa) number of amino acids in the V3 region and positions 11
and 25 are highlighted. (A) Amino acid alignment of 5 populations present in Du36, as seen in accompanying gel. (B) Amino acid alignments of variants present in 1
R5 and 3 DM isolates.
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CXCR4-using viruses (75%) had changes in the crown motif
(GPGQ). These changes were mostly at position 18, but amino
acid substitutions were also seen at positions 16 and 17.
Determining subtype C V3 characteristics associated with
CXCR4 usage
Consensus sequences were compiled for the 16 CCR5 and
16 CXCR4 sequences investigated in this study. There was
sequence homology for 26 of the 35 amino acids between the
CCR5- and CXCR4-using isolates (Fig. 6A). Amino acid
substitutions associated with the CXCR4-using data set were
seen at position 5 with N being replaced by G and position 19
associated with either A or T. The consensus sequence ofCXCR4-using viruses had a 2 amino acid insertion between
positions 13 and 14, as well as a further seven variable (X)
amino acid positions (11, 12, 18, 23, 24, 25 and 34) compared to
the CCR5 consensus. The crown motif of the CXCR4
consensus changed from GPGQ to GPGX, where X was
usually an R, Y, K or H amino acid. Further analysis of the
crown revealed additional genetic differences between CCR5
and CXCR4-using isolates that were of particular interest as
such differences have not previously been fully explored.
In order to extend this analysis, we combined these data with
previously published subtype C sequences from the Los Alamos
database. This included 91 single patient sequences with
determined CCR5 coreceptor usage and 17 sequences annotated
as SI or CXCR4-using. This reflects the limited numbers of
CXCR4-using subtype C isolates available for analysis, and the
Fig. 4. Comparison of (A) V3 amino acid length and (B) V3 amino acid charge
of HIV-1 subtype C isolates able to use CCR5 and CXCR4.
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33. Since CXCR4 usage among HIV-1 subtype B has been more
extensively studied, we performed a comparison with HIV-1
subtype B V3 sequences (also obtained from Los Alamos
database). Using these larger data sets, we determined which
genetic changes were associated with CXCR4 usage. For both
subtypes B and C, there were significant associations with
variable lengths, increase in charge and loss of the glycosylation
site within the V3 region of CXCR4-using sequences (using
contingency tables and Fisher's Exact Test, p<0.001). How-
ever, changes in the GPGQ crown motif were only significant
for subtype C CXCR4-using viruses (p<0.001) but not for
GPGR in subtype B (p=0.4). Analyses showed that, while there
was some variation at positions 16 (P) and 18 (R) in subtype B,
this did not differ significantly between isolates that used CCR5
and those that used CXCR4 (Fig. 6B). This is in contrast to
HIV-1 subtype C CXCR4-using isolates which showed marked
variation particularly at position 18 from the subtype C GPGQ
consensus. The entropy difference was also compared between
the two data sets within each subtype using a web-based tool
(ENTROPY-2 from Los Alamos data base) (Korber et al.,
1994). This tool allows for a Monte Carlo randomisation within
the data set, thereby providing statistical confidence of the
variability associated within each data set. The analysis
confirmed that there were significant variabilities (p<0.01)
within the crown motif between the CCR5 and CXCR4 data set
within HIV-1 subtype C, whereas this was not seen in thesubtype B data sets (data not shown). Thus, there appears to be
an appreciable difference between HIV-1 subtype C and B
crown motif sequences and coreceptor usage.
Discussion
A subtype C-specific V3-HTA was used to examine 32
subtype C isolates with known biological phenotypes (16 R5 and
16 R5X4 or X4 isolates). Results indicated that there were
sufficient genetic differences to discriminate between R5 viruses
and those phenotyped as R5X4 and X4. Sequence analysis of the
V3 region showed that CXCR4-using viruses were often
associated with an increased number of positively charged
amino acids, loss of a potential glycosylation site, as well as
variable lengths. Compared to HIV-1 subtype B V3 sequences,
where the consensus sequence at the GPGR crown did not differ
between CCR5 and CXCR4-using isolates, the GPGQ subtype
C consensus was heavily substituted in CXCR4-using viruses.
The V3-HTA has proven to be a rapid screening method to
detect V3 evolutionary variants of HIV-1 subtype B and C
viruses (Nelson et al., 1997, 2000; Ping et al., 1999). This assay
measures distinct genetic features such as insertions, deletions
or clustered amino acid changes that influence the mobility of
the V3 heteroduplex. These characteristics are frequently
associated with the X4-like phenotype, and using this assay, it
has been possible to screen for X4 variants (Nelson et al., 1997).
In a previous study of subtype C by Ping et al. (1999), no X4-
like subtype C isolates were identified using a V3-HTA. This is
because this study did not focus on subjects with low CD4 cell
counts where X4 variants are more likely to be found, even in
subtype C where such variants are rare. Here we selected
subtype C viruses with experimentally determined phenotypes
including a large collection of X4 variants. Using a subtype C
V3-HTA, most R5 isolates had homogeneous populations with
mobility ratios above 0.90. This included R5 isolates from
patients with advanced disease where more heterogeneous
sequences might be expected (McNearney et al., 1992). The
highly conserved nature of subtype C V3 R5 isolates was also
noted in the study by Ping and others (1999). The R5X4 and X4
isolates had a broader range of mobility ratios that were
generally lower than 0.90. The X4 isolates had homogenous
populations in the V3-HTA, whereas the DM isolates were
associated with multiple variants as evidenced by multiple
bands. Further analysis of these DM isolates indicated that they
comprised of mixtures of variants.
A limiting factor within this study was the biased selection of
samples as the ratio of R5 and X4 variants selected in this study
is not reflective of prevalence of these viruses within the general
populations of HIV-1 subtype C. The low numbers sampled in
each class might influence the sensitivity and specificity of this
assay and could therefore either improve or decline as better
sampling is achieved. Among 231HIV-1 subtype C viral isolates
in our laboratory, only 10%were found to be CXCR4-using, and
this was significantly correlated with a CD4 count of <200 cells/
μl (p=0.0021, Fisher's Exact Test). Although V3-HTA was
sensitive in detecting most of the slower migrating X4 variants,
this sensitivity would decrease with larger data sets due to the
Fig. 5. Variation in the V3 region of CCR5 and CXCR4-using isolates of HIV-1 subtype C. (A) Entropy plot representing the variation at each amino acid site for CCR5
usage and CXCR4 usage. The potential N-glycosylation site N-[X]-T, amino acid positions 11 and 25, and crown motif are indicated. (B) Distribution of amino acids
in the V3 region of 16 CCR5- and 16 CXCR4-using variants (numbers indicate frequency in total of 16 viruses).
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of CCR5 variants with genotypic characteristics that cause slow
migration (such as deletions and insertions). Similarly, the
frequency of false positives (i.e. slow migrating R5 variants)
would decrease the specificity. Thus, since the V3-HTA is more
reflective of sample complexity, the mobility ratio criteria could
vary if a larger data set was used. Despite these considerations,
these data suggest that the V3-HTAwas a useful screening tool to
evaluate sample complexity and could assist in cloning
strategies to investigate the V3 differences between CCR5-
and CXCR4-using viruses.
A further caveat of this study was the selection of a single
variant from the 4 DM viruses for inclusion in the data set.
Since we did not know the coreceptor usage of individual
clones, we selected the one with the genetic properties most
commonly associated with CXCR4 usage. However, an
analysis that included all the variants from the 4 DM isolates
did not show significantly different outcomes (data not shown).
Comparisons between the CCR5 and CXCR4 data sets
revealed differences in charge and length between CCR5-and CXCR4-using subtype C viruses. The V3 loops of
CXCR4-using viruses were usually more variable and
positively charged, previously shown to be associated with
CXCR4 usage (De Jong et al., 1992). The increased length was
usually due to one or two amino acid insertions between
position 13 and 14, with amino acids I and G being the most
common. Almost all CXCR4-using isolates had a high V3
charge above +4.5. This was due to the presence of increased
numbers of K and R residues that were scattered throughout
the V3 of CXCR4-using viruses, including positions 11 and 25
which are indicative of SI viruses in subtype B (Fouchier et al.,
1992). Although the 11/25 rule is used for tropism determina-
tion, it is not clear whether basic amino acid substitutions at
these sites are sufficient or necessary for CXCR4 usage
(Kuiken et al., 1992; Nelson et al., 2000). In this study, these
positions were not necessarily associated with positively
charged amino acids in CXCR4-using viruses, although there
was increased variation at these positions compared to R5
viruses. Nevertheless, similar to subtype B (Shioda et al.,
1992), CXCR4 usage in subtype C was rarely due to a single
Fig. 6. (A) Consensus V3 sequences from CCR5- and CXCR4-using HIV-1 subtype C isolates. Amino acids within the CXCR4-using consensus that differ from the
CCR5 consensus are highlighted and the crown motif is boxed. Variable (X) and identical (.) amino acids are indicated. (B) Comparison of amino acid variation in the
V3 crown of subtype C isolates from Los Alamos and this study (107 CCR5 and 33 SI) (p<0.0001) and subtype B isolates from Los Alamos (99 CCR5 and 30
CXCR4).
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that increased the length and charge of the V3 loop.
All the R5 isolates in this study had a potential N-
glycosylation site at positions 6–8 within the V3 region. Most
early viruses, able to use CCR5, have this glycan, suggesting
that it is needed for CCR5 interaction (Polzer et al., 2002). As
immune pressure decreases with disease progression, viruses
lacking this glycan able to use CXCR4 have been shown to
emerge (Pollakis et al., 2004; Polzer et al., 2002). The loss of
this glycan has also been shown to assist in more efficient use of
CXCR4 and thus might be an important factor in the switching
of R5X4 to X4 viruses (Nabatov et al., 2004; Polzer et al.,
2002). Four of the 16 CXCR4-using viruses in this study lacked
this potential glycosylation site, suggesting that in subtype C
this site may play a similar role. The highly conserved nature of
this glycan in R5 subtype C viruses suggests it is crucial for
interaction with CCR5 possibly by masking surrounding
positively charged amino acids at the N-terminus of the V3
region (Hartley et al., 2005). Pollakis and others (2001) have
speculated that the high frequency of V3 glycosylation within
subtype C viruses might constrain the envelope structure
promoting the use of CCR5 and thereby increase its transmis-
sion efficiency.
Most published subtype C isolates have a GPGQ crown
motif, whereas the consensus subtype B generally contains a
GPGR motif irrespective of coreceptor usage (Milich et al.,
1997). In this study, CCR5-using viruses had the expected
GPGQ crown, whereas this changed to GPGX, with X being R,
K, H or Y in CXCR4-using isolates. Although changes within
the crown of subtype C viruses have been observed by others,
the possible importance of this for coreceptor usage has not been
discussed (Abebe et al., 1999; Batra et al., 2000; Bjorndal et al.,
1999; Cilliers et al., 2003; Johnston et al., 2003; Ping et al.,
1999). Extending this analysis to sequences in the Los Alamosdatabase confirms the findings of a conserved crown motif in
CCR5-using viruses and variable motif in CXCR4-using
viruses. There were very few viruses with biologically
determined CXCR4 coreceptor usage available, with most of
the sequences annotated as SI phenotype (suggestive of R5X4
and X4 viruses). Nevertheless, the changes in the crown motif
associated with CXCR4 usage were confirmed in the larger data
set. Secondary structure prediction suggests that the GPGX
forms a beta turn, and amino acid changes within this motif are
critical determinants of coreceptor usage (Cormier and Dragic,
2002; Hartley et al., 2005; Hu et al., 2000; Pollakis et al., 2004;
Shimizu et al., 1999; Suphaphiphat et al., 2003). Confirmation
of the role of the V3 crown in coreceptor selection has been
shown by recent structural studies (Huang et al., 2005; Watabe
et al., 2006). In subtype B position 18 in the GPGR, crown was
found to be less variable in X4 viruses, suggesting a functional
role for R in CXCR4 usage (Resch et al., 2001), possibly
predisposing subtype B viruses to using CXCR4. In subtype C,
arginine (R) was the most frequent amino acid at position 18 in
CXCR4-using isolates. Thus, one route to CXCR4 usage may
require GPGQ to first undergo a change at position 18 to
arginine (R) increasing the charge and/or altering the conforma-
tion of V3, as proposed by Hartley et al. (2005). Previous studies
have shown that the transition from a R5 to X4 requires few
genetic changes (at least within the V3), although these
transitional intermediates may be less fit, accounting for the
low frequency of X4 viruses in subtype C (Pastore et al., 2004).
In conclusion, changes within the V3 region such as
increased amino acid charge, insertions, specific amino acid
variation and loss of the potential glycosylation site are all
factors that play a role in CXCR4 usage of subtype C viruses as
have been reported in other subtypes. Although the numbers of
CXCR4-using isolates in subtype C are limited, there was a
noteworthy difference between the crown motif of CCR5 and
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additional virological adaptation within subtype C viruses that
allows, but also limits, these viruses to acquire the ability to use
CXCR4 as a coreceptor.
Materials and methods
Isolation and coreceptor usage of HIV-1 subtype C viruses
Viral isolates were selected from previously described
cohorts from our laboratory. This included isolates from adult
patients with advanced HIV-1 disease [SW, CM, PCP] (Cilliers
et al., 2003), sex workers with acute HIV-1 infection [Du]
(Williamson et al., 2003) and one patient failing anti-retroviral
treatment (Cilliers et al., 2004). Some isolates originated from a
paediatric cohort of slow (TM) and rapidly progressing children
(RP) (Choge et al., 2006). Levels of virus in plasma were
measured using the Versant HIV-1 RNA 3.0 assay (bDNA from
Bayer Nucleic Acid Diagnostics), and CD4 counts were
determined using a FACS count (Becton Dickinson, San Jose,
CA). Viral isolates were tested for their ability to replicate in
U87.CD4 cells transfected with either CCR5 or CXCR4, as
previously described (Cilliers et al., 2003; Morris et al., 2001).
Biotype was assigned based on the production of p24-antigen in
the CCR5 (R5 isolate) or CXCR4 (X4 isolate) cell lines. Isolates
able to use both coreceptors with comparable efficiencies or
within 10% of the major coreceptor were considered dualtropic
(R5X4) (Berger et al., 1998).
Viral RNA isolation and RT-PCR
Viral RNA of each isolate was extracted from PBMC culture
supernatant using a MagnaPure LC Isolation station and the
Total Nucleic Acid isolation kit (Roche Applied Science,
Penzberg, Germany). RT-PCR was performed with primers C+
V3 (5′-ATA GTA CAT CTT AAT CAA TCT GTA GAA ATT-
3′) and C−V3 (5′-CCA TTT ATC TTT ACT AAT GTT ACA
ATG TGC-3′), generating a 159 bp product as described
(Nelson et al., 1997; Ping et al., 1999). PCR products were
purified using the High Pure PCR Product Purification kit
(Roche Diagnostics GmbH, Mannheim, Germany).
V3-HTA
V3-HTA probe construction and labelling were done as
previously described by Nelson et al. (1997) and Ping et al.
(1999). The probe from the plasmid (D516-11) originating from
a subtype C R5 virus and with only three nucleotide differences
from the subtype C V3 consensus was used (Ping et al., 1999).
Single-stranded probe labelling was done by digesting plasmid
D516-11 with BamH1 (Amersham Pharmacia Biotech, UK),
end-labelling at room temperature with a mixture containing
12.5 μCi 35S-dATP (Amersham Pharmacia Biotech, UK),
unlabelled dGTP and Klenow DNA polymerase I (Amersham
Pharmacia Biotech, UK). The probe was removed from the
vector by digestion with SpeI (Amersham Pharmacia Biotech,
UK) and purified using the High Pure PCR purification kit(Roche Diagnostics GmbH, Mannheim, Germany) into a final
volume of 50 μl. Heteroduplexes were formed between the
probe and PCR product in a 10 μl reaction containing 5 μl PCR
product, 3 μl labelled probe, 1 μl annealing buffer (1 M NaCl,
100 mM Tris–HCl [pH 7.5], 20 mM EDTA) and 1 μMof the C+
V3 primer denatured at 95 °C for 2 min. The reactions were
cooled at room temperature for 10 min and the heteroduplexes
separated in non-denaturing 12% polyacrylamide gels as
described by Nelson et al. (1997). The dried gels were exposed
to autoradiograms (BioMax MR, Kodak). Heteroduplex
mobility ratios were determined by measuring the mobility of
the slowest heteroduplexes (highest bands in the gel) of each
sample and dividing it by the mobility of the probe
homoduplex. The PCR products from samples with single
bands were sequenced using an ABI PRISM 3100 genetic
analyser with ABI PRISM BigDye Terminator v3.1 Cycle
Sequencing kit (Applied Biosystems).
Cloning
Isolates with multiple variants were selected for cloning.
Purified PCR products were cloned into the pGEMTeasy vector
(Promega, USA) and individual molecular clones were screened
by HTA and sequenced as described above.
Analysis
All sequences were aligned with ClustalX, predicted protein
translations were performed using BioEdit (version 5.0.9),
phylogenetic analysis and genetic distances were determined
using the MEGA program (version 2.1). The consensus
sequences for isolates that used CCR5 and CXCR4 were
determined using BioEdit. Additional subtype B and C V3
sequences (single sequence per patient) were downloaded from
the Los Alamos database (http://www.hiv.lanl.gov). The sub-
type B data set contained 129 sequences with known coreceptor
usage (99 CCR5 and 30 CXCR4) and the subtype C data set 91
CCR5 viruses and 17 SI viruses (since limited numbers of
subtype C viruses with biologically determined CXCR4 usage
were available).
Nucleotide sequence accession numbers
The sequence data for the V3 regions obtained in this study
have been submitted to GenBank under the following accession
numbers: DQ898249–DQ898274. The following sequences are
identical to previous submissions to GenBank: AY230878,
AY170658, AY529667, AY529672, AY529677, AY529676,
AY529678, AY529679, AY043173, AY043174, AY529675,
AF411966, DQ235616, DQ235638.
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